Statin Therapy in HIGH-Risk Individuals with NORMal Coronary Arteries: The HIGH-NORM Study

Kyeong-Hyeon Chun1, Jung Mi Park2, Chan Joo Lee1

  • 1Division of Cardiology, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine.

Insights

Statin use did not reduce cardiovascular events in high-risk individuals with normal coronary arteries. Personalized lipid-lowering therapy may be more beneficial for this patient group.

Area of Science:

  • Cardiology
  • Preventive Medicine
  • Medical Imaging

Background:

  • Cardiovascular disease risk assessment can be complex, especially when risk scores conflict with imaging findings.
  • Coronary computed tomography angiography (CCTA) provides anatomical detail of coronary arteries.
  • Identifying optimal preventive strategies for high-risk individuals with non-obstructive coronary artery disease is crucial.

Purpose of the Study:

  • To investigate the association between statin use and cardiovascular benefit in high-risk individuals with normal coronary arteries on CCTA.
  • To determine if statins confer protection against major adverse cardiovascular and cerebrovascular events (MACCEs) in this specific population.

Main Methods:

  • Retrospective analysis of 3,389 asymptomatic individuals with normal/near-normal CCTA and high/very-high cardiovascular risk.
  • Propensity score matching created a cohort of 906 individuals (302 statin users, 604 controls).
  • Primary outcome was MACCEs (cardiovascular death, myocardial infarction, revascularization, ischemic stroke) over a median of 5.8 years.

Main Results:

  • No significant difference in MACCE rates between statin users and controls (7.4 vs. 5.6 events/1,000 person-years; HR 1.04; p=0.92).
  • Kaplan-Meier analysis confirmed similar MACCE rates (p=0.91) in both groups.
  • Age, male sex, and smoking were independently associated with MACCEs, but no factors modified the statin-MACCE relationship.

Conclusions:

  • Statin therapy was not associated with a reduction in cardiovascular risk for high-risk individuals with normal coronary arteries.
  • Current guidelines may need refinement, suggesting a need for more individualized lipid-lowering strategies in this population.
Abstract

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
80
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.0K
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
424
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
74
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
54
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
62